Product logins

Find logins to all Clarivate products below.


Keval Vasavada

Director, Consulting

Keval Vasavada comes with a right mix of consulting as well as industry experience in pharmaceutical and life sciences.

He holds over 13 years of experience spanning corporate strategy, operations, new process set-up, new product launches, corporate finance, fund raising and commercial deals. Prior to Clarivate, Keval worked with Cipla Pharmaceuticals and IQVIA Consulting.

He has worked on developing disruptive, competitive and sustainable business model for biosimilar business in his previous assignment. He understands the nuances of biopharma manufacturing and has spearheaded commercial discussions with top suppliers of biopharma equipment in the past.

During his consulting stint, he has led projects involving asset portfolio strategy, market entry strategy, commercial due diligence, opportunity assessment for novel therapies in Japan, Asia-Pacific, US, and Europe. He has a rich exposure of working across a breadth of therapeutic areas involving oncology, immunology, neurology, respiratory, rare diseases, and metabolic disorders.

Keval has completed his MBA from the prestigious Indian Institute of Management, Lucknow (India) and did his B.Tech. in Dairy Technology from Dairy Science College, Anand (Gujarat, India).

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全